Abstract


Abstract

Whitehead RP, McCoy S, Wollner IS, Wong L, Harker WG, Hoff PM, Gold PJ, Billingsley KG, Blanke CD. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. Proc ASCO 2006; Vol. 24, No. 18S (June 20 Supplement). 2006


Lucas Wong, MD, FACP

Abstract


Publications

Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0120. Accepted for publication in Breast Cancer Research and Treatment. xxxx


May 1, 2014
Lucas Wong, MD, FACP
Reference List

Publications


May 1, 2014
Lucas Wong, MD, FACP
Reference List

Publications


Papers Published


May 1, 2014 5
Lucas Wong, MD, FACP
Reference List

Papers Published


Poster Presentation

Bryan K. Kee, Rebecca Slack, Todd S. Crocenzi, Lucas Wong, Benjamin Esparaz, Michael J. Overman, Katrina Y. Glover, Jeffrey Morris, Michael Fisch; A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I). Poster presentation at the The University of Texas MD Anderson Cancer Center, Houston, TX; Providence Cancer Center, Portland, OR; Scott & White Cancer Research Institute, Temple, TX; Cancer Care Specialists of Central Illinois, Decatur, IL; Tyler Hematology Concology, Tyler, TX **2013**


Shuchi Sumant Pandya, Lucas Wong, Andrea J. Bullock, Stephen A. Grabelsky, Merrill Kingman Shum, Joseph Shan, Kerstin B. Menander, Tony R. Reid; Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma. Poster presentation at Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; Scott & White Cancer Research Institute, Temple, TX; Beth Israel Deaconess Medical Center, Boston, MA; Center for Hem Onc, Boca Raton, FL; Oncology Institute of Hope and Innovation, Whittier, CA; Peregrine Pharmaceuticals, Inc., Tustin, CA; UC San Diego Moores Cancer Center, La Jolla, CA **2013**

Lucas Wong, MD, FACP  
Reference List  

Poster Presentation  


John Sarantopoulos, Antje Hoering, Timothy W. Synold, Devalingam Mahalingam, Ding Wang, Heinz-Josef Lenz, Pat O'Rourke, Rachel Sexton, Peter J. Van Veldhuizen, Monica M. Mita, Lucas Wong, Alain C. Mita, Anthony B. El-Khoueiry, Vincent M. Chung, David R. Gandara, Sheela Tejwani, Naoko Takebe, Chris H.M. Takimoto, S. Percy Ivy, Razelle Kurzrock; Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction. Poster Presentation at the Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX; SWOG Statistical Center, Seattle, WA; City of Hope, Duarte, CA; Josephine Ford Cancer Center/Henry Ford Health System, Detroit, MI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; University of Kansas Cancer Center, Westwood, KS; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX; Scott and White Clinic, Temple, TX; University of California Davis Cancer Center, Sacramento, CA; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; University of Texas M. D. Anderson Cancer Center, Houston, TX 2012


May 1, 2014
Lucas Wong, MD, FACP
Reference List

Poster Presentation


Lucas Wong, MD, FACP
Reference List

Poster Presentation

